- Home
- RMBS vs BBIO Comparison
RMBS vs BBIO Comparison
Compare RMBS & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RMBS
- BBIO
- Stock Information
- Founded
- RMBS 1990
- BBIO 2015
- Country
- RMBS United States
- BBIO United States
- Employees
- RMBS N/A
- BBIO N/A
- Industry
- RMBS Semiconductors
- BBIO Biotechnology: Pharmaceutical Preparations
- Sector
- RMBS Technology
- BBIO Health Care
- Exchange
- RMBS Nasdaq
- BBIO Nasdaq
- Market Cap
- RMBS 5.8B
- BBIO 5.6B
- IPO Year
- RMBS 1997
- BBIO 2019
- Fundamental
- Price
- RMBS $61.92
- BBIO $33.79
- Analyst Decision
- RMBS Strong Buy
- BBIO Strong Buy
- Analyst Count
- RMBS 5
- BBIO 13
- Target Price
- RMBS $77.20
- BBIO $48.33
- AVG Volume (30 Days)
- RMBS 836.0K
- BBIO 2.6M
- Earning Date
- RMBS 02-03-2025
- BBIO 02-20-2025
- Dividend Yield
- RMBS N/A
- BBIO N/A
- EPS Growth
- RMBS N/A
- BBIO N/A
- EPS
- RMBS 1.61
- BBIO N/A
- Revenue
- RMBS $517,746,999.00
- BBIO $217,765,000.00
- Revenue This Year
- RMBS $24.44
- BBIO $2,309.33
- Revenue Next Year
- RMBS $21.75
- BBIO N/A
- P/E Ratio
- RMBS $38.50
- BBIO N/A
- Revenue Growth
- RMBS 12.25
- BBIO 2209.77
- 52 Week Low
- RMBS $37.42
- BBIO $21.62
- 52 Week High
- RMBS $76.38
- BBIO $41.04
- Technical
- Relative Strength Index (RSI)
- RMBS 69.22
- BBIO 68.27
- Support Level
- RMBS $54.43
- BBIO $33.73
- Resistance Level
- RMBS $58.50
- BBIO $36.24
- Average True Range (ATR)
- RMBS 1.73
- BBIO 1.55
- MACD
- RMBS 0.59
- BBIO 0.60
- Stochastic Oscillator
- RMBS 98.28
- BBIO 72.81
About RMBS Rambus Inc.
Rambus Inc is a semiconductor solutions provider offering high-speed, high-security computer chips and Silicon intellectual property. The company's key products include memory interface chips, built for high speed and efficiency; silicon IP, providing high-speed memory and chip-to-chip connection technology; and architecture licenses, which allow customers to use portions of Rambus' patented inventions for their own digital electronics. The firm receives the majority of its revenue from the United States, Taiwan, Asia, Japan, and Singapore.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.